Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Implementation of Enterprise Resource Planning computer system completed, President & CEO Ross Blechman tells analysts during Q3 conference call Nov. 14. ERP system, which Twinlab spent close to $3 mil. on in the past nine months, integrates purchasing, manufacturing, fulfillment, financial operations and will help improve managerial control throughout company, exec says. Firm's fill rates are up over 90% after falling to 70% range in the summer. Twinlab also announces new 10% cut in salaried workforce, a move expected to save $2.2 mil., and reduced personnel costs "at the hourly level by approximately $1 mil." Quarterly and nine-month net sales were down 20% and 15.1% to $54 mil. and $156.8 mil., respectively. Firm recorded net losses of $1.8 mil. for the quarter, $24.7 mil. for the nine months...

You may also be interested in...

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement

The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately. 

ICER Gives Allergan, Biohaven CGRP Inhibitors Slight Edge Over Lilly’s Reyvow

ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts